MDV Medivation

SAN FRANCISCO, March 19 /PRNewswire-FirstCall/ -- Medivation, Inc. (AMEX:MDV) today announced that six-month results from its randomized, double-blinded, placebo-controlled Phase 2 efficacy trial of Dimebon(TM) in patients with mild-to-moderate Alzheimer's disease demonstrated that patients treated with Dimebon were significantly improved compared to patients taking placebo on all five efficacy endpoints studied, which assessed cognitive function, memory, ability to perform tasks of daily living, global function and behavior. Full top-line data from this trial were presented yesterday for the first time as an oral presentation (abstract #1662) at the 8th International Conference on Alzheimer's and Parkinson's Diseases: Progress and New Perspectives, in Salzburg, Austria, by the study's lead investigator, Rachelle S. Doody, M.D., Ph.D., the Effie Marie Cain Chair in Alzheimer's Disease Research at the Alzheimer's Disease and Memory Disorders Center, Baylor College of Medicine in Houston. New data presented in Salzburg included the magnitude and levels of statistical significance by which the Dimebon-treated patients outperformed the placebo-treated patients on the Mini Mental State Exam (MMSE: p